Fairmont Chateau Whistler Floorplan
This meeting was rescheduled and may have a different Meeting Program and Scholarships/Awards
Here are the related meetings in 2023:
Precision Genome Engineering (X2)
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
MEETING POSTPONED: Precision Genome Engineering (Q5)
Organizer(s) Jacob E. Corn, Kathy K. Niakan and Cecilia Cotta-Ramusino
February 13—17, 2022
Fairmont Chateau Whistler • Whistler, BC Canada
Abstract Deadline: Nov 16, 2021
Scholarship Deadline: Nov 16, 2021
Discounted Registration Deadline: Dec 15, 2021
Sponsored by Biogen, Regeneron Pharmaceuticals, Inc., TCR² Therapeutics and Takeda Pharmaceutical Company Limited
Joint Meeting:
MEETING POSTPONED: Emerging Cellular Therapies (Q6)
Summary of Meeting:
Precision genome engineering has completely revolutionized biological research and is making groundbreaking inroads to therapies. Progress is rapid and the ability for researchers to meet and network is essential in order to stay updated with the latest advances in the field. This conference will focus on new fundamental CRISPR-Cas biology, creation of new genome engineering tools (both CRISPR-Cas and otherwise), provide updates on new biological applications, and discuss the latest advances on applications moving towards market, such as therapies and agricultural developments. The Keystone Symposia conference on CRISPR has been a benchmark of the field and draws large audiences. The continued development of creative new tools and further progress towards real-world application will be a big attraction for participants. This conference will also include workshops and panels on ethical questions that will enrich the scientific program. Finally, this meeting will be held jointly with the Keystone Symposia conference Emerging Cellular Therapies. This is an ideal pairing as genome engineering has become de rigueur in this arena. Genome engineer attendees will benefit by learning pain points and missing pieces in the field of cellular therapy, and cell therapy attendees will benefit by hearing about the latest and greatest coming at break-neck speed from the genome engineering field.
View Scholarships/Awards
Precision genome engineering has completely revolutionized biological research and is making groundbreaking inroads to therapies. Progress is rapid and the ability for researchers to meet and network is essential in order to stay updated with the latest advances in the field. This conference will focus on new fundamental CRISPR-Cas biology, creation of new genome engineering tools (both CRISPR-Cas and otherwise), provide updates on new biological applications, and discuss the latest advances on applications moving towards market, such as therapies and agricultural developments. The Keystone Symposia conference on CRISPR has been a benchmark of the field and draws large audiences. The continued development of creative new tools and further progress towards real-world application will be a big attraction for participants. This conference will also include workshops and panels on ethical questions that will enrich the scientific program. Finally, this meeting will be held jointly with the Keystone Symposia conference Emerging Cellular Therapies. This is an ideal pairing as genome engineering has become de rigueur in this arena. Genome engineer attendees will benefit by learning pain points and missing pieces in the field of cellular therapy, and cell therapy attendees will benefit by hearing about the latest and greatest coming at break-neck speed from the genome engineering field.
View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference
The meeting will begin on Sunday, February 13 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, February 17 with a closing plenary session from 17:00 to 19:30, followed by a social hour. We recommend return travel on Friday, February 18 in order to fully experience the meeting.
SUNDAY, FEBRUARY 13
MONDAY, FEBRUARY 14
TUESDAY, FEBRUARY 15
WEDNESDAY, FEBRUARY 16
THURSDAY, FEBRUARY 17
FRIDAY, FEBRUARY 18
Conference Program Print | View meeting in 12 hr (am/pm) time
The meeting will begin on Sunday, February 13 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, February 17 with a closing plenary session from 17:00 to 19:30, followed by a social hour. We recommend return travel on Friday, February 18 in order to fully experience the meeting.
SUNDAY, FEBRUARY 13
18:00—20:00
Welcome Mixer
No registration fees are used to fund alcohol served at this function.
08:00—09:30
Welcome and Keynote Session (Joint)
David R. Liu,
Broad Institute, HHMI, and Harvard University, USA
Base Editing and Prime Editing: Precision Gene Editing Without Double-Strand DNA Breaks
Base Editing and Prime Editing: Precision Gene Editing Without Double-Strand DNA Breaks
Alain Fischer,
Institut Imagine, France
Genetic Correction of Congenital Immune Deficiencies
Genetic Correction of Congenital Immune Deficiencies
Coffee Break
09:50—11:45
Hematopoietic and Pluripotent Stem Cell Editing (Joint)
Paula M. Cannon,
University of Southern California, Keck School of Medicine, USA
Gene Editing B Cells for Single-Chain Antibodies
Gene Editing B Cells for Single-Chain Antibodies
Luigi M. Naldini,
San Raffaele Telethon Institute for Gene Therapy, Italy
HSC Editing
HSC Editing
Sjoukje J.C. van der Stegen,
Fate Therapeutics, USA
iPS-Derived T Cells
iPS-Derived T Cells
Bernhard Lehnertz,
ExCellThera Inc., Canada
Short Talk: HLF Expression Defines the Human Hematopoietic Stem Cell State and Can Be Exploited to Optimize HSC-Specific Gene Editing Parameters
Short Talk: HLF Expression Defines the Human Hematopoietic Stem Cell State and Can Be Exploited to Optimize HSC-Specific Gene Editing Parameters
14:30—16:30
Workshop 1: Genome Editing without DSB
Gabriel L. Butterfield,
Duke University, USA
Uncovering Novel Epigenome Editing Domains
Uncovering Novel Epigenome Editing Domains
Alejandra Falla,
Vor Biopharma, USA
Multiplex Base Editing in Human Hematopoietic Stem and Progenitor Cells (HSPCs) Enables Efficient Removal of Multiple Surface Antigens in Acute Myeloid Leukemia (AML) Immunotherapy
Multiplex Base Editing in Human Hematopoietic Stem and Progenitor Cells (HSPCs) Enables Efficient Removal of Multiple Surface Antigens in Acute Myeloid Leukemia (AML) Immunotherapy
Jonas Koeppel,
Wellcome Sanger Institute, UK
Predicting Efficiency of Writing Short Sequences into the Genome using Prime Editing
Predicting Efficiency of Writing Short Sequences into the Genome using Prime Editing
Josh Tycko,
Stanford University, USA
Systematic Identification of Cell Type- and Target-Dependencies for Human Transcriptional Effectors
Systematic Identification of Cell Type- and Target-Dependencies for Human Transcriptional Effectors
Minja D. Velimirovic†,
Harvard Medical School BWH, USA
Peptide Fusion Improves Prime Editing Efficiency
Peptide Fusion Improves Prime Editing Efficiency
Marcus B. Noyes,
New York University School of Medicine, USA
Reprogramming Transcription Factors for Epigenetic Editing
Reprogramming Transcription Factors for Epigenetic Editing
Junhong Choi,
University of Washington, USA
A Temporally Resolved, Multiplex Molecular Recorder Based on Sequential Genome Editing
A Temporally Resolved, Multiplex Molecular Recorder Based on Sequential Genome Editing
Tessa Nicole Morin,
University of British Columbia, Canada
Safety of Genome Editing: Development of a Fluorescent Model System to Investigate Reducing Off-Target Genome Edits by Base Editors
Safety of Genome Editing: Development of a Fluorescent Model System to Investigate Reducing Off-Target Genome Edits by Base Editors
17:00—19:00
CRISPR-Cas Technology I
Jonathan S. Weissman,
Whitehead Institute, HHMI, and MIT, USA
Engineering without Cutting
Engineering without Cutting
Alexis C. Komor,
University of California, San Diego, USA
Cellular Processing of Base Editor Intermediates
Cellular Processing of Base Editor Intermediates
Omar Abudayyeh,
Massachusetts Institute of Technology, USA
Short Talk: Drag-and-Drop Genome Insertion without DNA Cleavage with CRISPR-Directed Integrases
Short Talk: Drag-and-Drop Genome Insertion without DNA Cleavage with CRISPR-Directed Integrases
17:00—19:00
T Cell Engineering
Stanley R. Riddell,
Fred Hutchinson Cancer Research Center, University of Washington, USA
T-Cell Subsets
T-Cell Subsets
Justin Eyquem,
University of California, San Francisco, USA
Precision Genome Engineering to Improve Adoptive Cell Therapies
Precision Genome Engineering to Improve Adoptive Cell Therapies
Zachary Steinhart,
Gladstone-UCSF Institute of Genomic Immunology, USA
Short Talk: CRISPR Activation and Interference Screens Decode Stimulation Responses in Primary Human T Cells
Short Talk: CRISPR Activation and Interference Screens Decode Stimulation Responses in Primary Human T Cells
Anton Dobrin,
Memorial Sloan Kettering Cancer Center, USA
Short Talk: Rationally Designed Synthetic Co-stimulation for Effective Adoptive Cell Therapy
Short Talk: Rationally Designed Synthetic Co-stimulation for Effective Adoptive Cell Therapy
Tom Barnes,
Orna Therapeutics, Inc., USA
Short Talk: In situ CAR Therapy Using oRNA™ Lipid Nanoparticles Regresses Tumors in Mice
Short Talk: In situ CAR Therapy Using oRNA™ Lipid Nanoparticles Regresses Tumors in Mice
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—11:00
CRISPR-Cas Technology II
Randall J. Platt,
ETH Zurich, Switzerland
Transcriptional Recording
Transcriptional Recording
J. Keith Joung,
Massachusetts General Hospital, USA
Targeted Epigenetic Editing of Human Genes with Engineered CRISPR and Zinc Finger Proteins
Targeted Epigenetic Editing of Human Genes with Engineered CRISPR and Zinc Finger Proteins
Coffee Break
Anna Christina Obenauf,
Research Institute of Molecular Pathology, Austria
Activatable Barcodes
Activatable Barcodes
Osamu Nureki,
University of Tokyo, Japan
Development of Novel DNA and RNA Base Editors based on their Cryo-EM Structures towards Medical Applications
Development of Novel DNA and RNA Base Editors based on their Cryo-EM Structures towards Medical Applications
Gregory R. Hoffman,
Arbor Biotechnology, USA
Short Talk: Engineering of CRISPR Cas12i to Enable Therapeutic Genome Editing
Short Talk: Engineering of CRISPR Cas12i to Enable Therapeutic Genome Editing
Erik J. Sontheimer,
University of Massachusetts Medical School, USA
Short Talk: Fully Modified and Stabilized Guides for SpyCas9 Genome Editing
Short Talk: Fully Modified and Stabilized Guides for SpyCas9 Genome Editing
Diego A. Velasquez Pulgarin,
Karolinska Institutet, Sweden
Short Talk: A Platform for Light-Induced Expression of Guide RNA Allows for Multipurpose Optogenetic CRISPR Gene Editing and Viral Delivery to Primary Mammalian Cells
Short Talk: A Platform for Light-Induced Expression of Guide RNA Allows for Multipurpose Optogenetic CRISPR Gene Editing and Viral Delivery to Primary Mammalian Cells
08:00—11:15
CARs and TCRs
Gianpietro Dotti,
UNC-Chapel Hill, USA
Improving CAR T Cell Therapy for Solid Tumors
Improving CAR T Cell Therapy for Solid Tumors
Marcela V. Maus,
Harvard Medical School, USA
New CAR Approaches
New CAR Approaches
Coffee Break
Nicholas R. J. Gascoigne,
National University of Singapore, Singapore
Exploiting Differences between CAR and TCR Signal Transduction to Improve CAR-T Function
Exploiting Differences between CAR and TCR Signal Transduction to Improve CAR-T Function
Thomas Blankenstein,
Max Delbruck Center for Molecular Medicine, Germany
TCR-Transgenic T Cells
TCR-Transgenic T Cells
Iowis Zhu,
, USA
Short Talk: Next-Generation Synthetic Receptors for the Enhanced Control of Cellular Immunotherapies
Short Talk: Next-Generation Synthetic Receptors for the Enhanced Control of Cellular Immunotherapies
Dana C. Gilmore,
TCR2, USA
Short Talk: Engineering Immunosuppressive T-Cell Receptor Fusion Construct Regulatory T Cells (TRuC-Tregs)
Short Talk: Engineering Immunosuppressive T-Cell Receptor Fusion Construct Regulatory T Cells (TRuC-Tregs)
Dylan J. Drakes,
Elicio Therapeutics, USA
Short Talk: Lymph Node Targeted Boosting with Cognate Amphiphile-peptide Vaccines Enhances TCR-T Cell Therapy to Eradicate Solid Tumors
Short Talk: Lymph Node Targeted Boosting with Cognate Amphiphile-peptide Vaccines Enhances TCR-T Cell Therapy to Eradicate Solid Tumors
14:30—16:30
Workshop 2: Therapeutic Applications (Joint)
Hari Jayaram,
Verve Therapeutics, USA
Comprehensive Approach to Evaluate Off-Target Editing for an in vivo Liver Base Editing Medicine Targeting the PCSK9 Gene
Comprehensive Approach to Evaluate Off-Target Editing for an in vivo Liver Base Editing Medicine Targeting the PCSK9 Gene
Parvathi Ranganathan,
Ohio State University, USA
CRISPR/Cas9 Gene Editing of MIR155HG in Primary Human T Cells to Prevent Acute Graft-versus-Host Disease
CRISPR/Cas9 Gene Editing of MIR155HG in Primary Human T Cells to Prevent Acute Graft-versus-Host Disease
Shengdar Q. Tsai†,
St. Jude Children's Research Hospital, USA
Genome Editing of Human HSCs to Induce Fetal Hemoglobin for Sickle Cell Disease Therapy
Genome Editing of Human HSCs to Induce Fetal Hemoglobin for Sickle Cell Disease Therapy
Thomas A. Fox,
University College London, UK
Therapeutic Gene Editing of T-Cells Corrects CTLA4 Insufficiency
Therapeutic Gene Editing of T-Cells Corrects CTLA4 Insufficiency
Veronica Gough,
Duke University, USA
A High-Throughput Screen for CRISPR-Cas9-Mediated Exon Deletion
A High-Throughput Screen for CRISPR-Cas9-Mediated Exon Deletion
Matthew G. Durrant,
UC Berkeley, USA
Large-scale Discovery of Recombinases for Integrating DNA into the Human Genome
Large-scale Discovery of Recombinases for Integrating DNA into the Human Genome
Mat Legut,
NY Genome Center, USA
Genome-Scale Screen for Synthetic Drivers of T-Cell Proliferation
Genome-Scale Screen for Synthetic Drivers of T-Cell Proliferation
Colby R. Maldini,
Beam Therapeutics, USA
Multiplex Base-edited CAR T Cells Resist Allorejection in vivo
Multiplex Base-edited CAR T Cells Resist Allorejection in vivo
14:30—16:30
Workshop 1: Therapeutic Applications (Joint)
Hari Jayaram†,
Verve Therapeutics, USA
Comprehensive Approach to Evaluate Off-Target Editing for an in vivo Liver Base Editing Medicine Targeting the PCSK9 Gene
Comprehensive Approach to Evaluate Off-Target Editing for an in vivo Liver Base Editing Medicine Targeting the PCSK9 Gene
Parvathi Ranganathan,
Ohio State University, USA
CRISPR/Cas9 Gene Editing of MIR155HG in Primary Human T Cells to Prevent Acute Graft-versus-Host Disease
CRISPR/Cas9 Gene Editing of MIR155HG in Primary Human T Cells to Prevent Acute Graft-versus-Host Disease
Shengdar Q. Tsai†,
St. Jude Children's Research Hospital, USA
Genome Editing of Human HSCs to Induce Fetal Hemoglobin for Sickle Cell Disease Therapy
Genome Editing of Human HSCs to Induce Fetal Hemoglobin for Sickle Cell Disease Therapy
Thomas A. Fox,
University College London, UK
Therapeutic Gene Editing of T-Cells Corrects CTLA4 Insufficiency.
Therapeutic Gene Editing of T-Cells Corrects CTLA4 Insufficiency.
Veronica Gough,
Duke University, USA
A High-Throughput Screen for CRISPR-Cas9-Mediated Exon Deletion
A High-Throughput Screen for CRISPR-Cas9-Mediated Exon Deletion
Matthew G. Durrant,
UC Berkeley, USA
Large-scale Discovery of Recombinases for Integrating DNA into the Human Genome
Large-scale Discovery of Recombinases for Integrating DNA into the Human Genome
Mat Legut,
NY Genome Center, USA
Genome-Scale Screen for Synthetic Drivers of T-Cell Proliferation
Genome-Scale Screen for Synthetic Drivers of T-Cell Proliferation
Colby R. Maldini,
Beam Therapeutics, USA
Multiplex Base-edited CAR T Cells Resist Allorejection in vivo
Multiplex Base-edited CAR T Cells Resist Allorejection in vivo
17:00—19:00
Non-CRISPR Tech
Samuel H. Sternberg,
Columbia University, USA
CRISPR Transposases
CRISPR Transposases
Zoltan Ivics,
Paul Ehrlich Institute, Germany
Transposons: Molecular Parasites Tamed for Therapeutic Cell Engineering
Transposons: Molecular Parasites Tamed for Therapeutic Cell Engineering
Cecilia Cotta-Ramusino,
Tessera Therapeutics, USA
Engineering Mobile Genetic Elements
Engineering Mobile Genetic Elements
Jonathan S. Gootenberg,
MIT, USA
Short Talk: Programmable RNA Targeting with the Single-Protein CRISPR Effector Cas7-11
Short Talk: Programmable RNA Targeting with the Single-Protein CRISPR Effector Cas7-11
Liliya Mukhametzyanova,
TU Dresden, Germany
Short Talk: Fusion of Designer-Recombinases for Efficient and Specific Correction of a Factor VIII Genomic Inversion
Short Talk: Fusion of Designer-Recombinases for Efficient and Specific Correction of a Factor VIII Genomic Inversion
17:00—19:00
Immune Escape – Antigen Escape
Aude G. Chapuis,
Fred Hutchinson Cancer Research Center, USA
Mechansims of Immune Escape to Trangenic TCR Therapy
Mechansims of Immune Escape to Trangenic TCR Therapy
Martin Pule,
University College London, UK
Strategies to Prevent Antigen Escape in CAR T Cell Therapies
Strategies to Prevent Antigen Escape in CAR T Cell Therapies
Anthony Rongvaux,
Fred Hutchinson Cancer Research Center, USA
Modelling Human Tumors using the MISTRG Mice
Modelling Human Tumors using the MISTRG Mice
Jessica Wagner,
St Jude Children's Research Hospital, USA
Short Talk: CAR T-cell Therapy Targeting ECM Proteins for Solid Tumors
Short Talk: CAR T-cell Therapy Targeting ECM Proteins for Solid Tumors
Sara Bolivar-Wagers,
University of Minnesota, USA
Short Talk: Prevention of Acute Graft-versus-host Disease Using an Orthogonal IL-2/IL-2Rβ System to Selectively Expand Regulatory T cells in vivo
Short Talk: Prevention of Acute Graft-versus-host Disease Using an Orthogonal IL-2/IL-2Rβ System to Selectively Expand Regulatory T cells in vivo
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—08:45
Keynote Address
Miriam Merad,
Mount Sinai School of Medicine, USA
Overcoming the Tumor Microenvironment
Overcoming the Tumor Microenvironment
08:00—11:00
DNA Repair
Maria Jasin,
Memorial Sloan Kettering Cancer Center, USA
CRISPR DNA Damage Response
CRISPR DNA Damage Response
Jacob E. Corn,
ETH Zürich, Switzerland
CRISPR DNA Repair
CRISPR DNA Repair
Coffee Break
Britt Adamson,
Princeton University, USA
Massively Parallel Profiling of Cas Pathways
Massively Parallel Profiling of Cas Pathways
Taekjip Ha,
Johns Hopkins University, USA
CRISPR Biophysics
CRISPR Biophysics
Zsolt Bodai,
University of California, San Diego, USA
Short Talk: Targeting Double-Strand Break Indel Byproducts with Secondary Guide RNAs Improves Cas9 HDR-Mediated Genome Editing Efficiencies
Short Talk: Targeting Double-Strand Break Indel Byproducts with Secondary Guide RNAs Improves Cas9 HDR-Mediated Genome Editing Efficiencies
Chris Richardson,
University of California, Santa Barbara, USA
Short Talk: Covalent Modification of Donor DNA Improves HDR in Primary Human Cells
Short Talk: Covalent Modification of Donor DNA Improves HDR in Primary Human Cells
Lazaros Lataniotis,
University of California, San Francisco, USA
Short Talk: Investigating the Indel-free Resolution of DNA Breaks with CRISPR/Cas9 in iPSCs
Short Talk: Investigating the Indel-free Resolution of DNA Breaks with CRISPR/Cas9 in iPSCs
08:45—11:30
T Cell Exhaustion
Andrea Schietinger,
Memorial Sloan Kettering Cancer Center, USA
Molecular and Epigenetic Mechanisms of Tumor-Specific T Cell Recognition and Exhaustion
Molecular and Epigenetic Mechanisms of Tumor-Specific T Cell Recognition and Exhaustion
Coffee Break
Dirk Hans Busch,
Technical University Munich, Germany
Improving Antigen-Specific Immunotherapy
Improving Antigen-Specific Immunotherapy
Axel Kallies,
University of Melbourne, Australia
Molecular Control of T-Cell Differentiation
Molecular Control of T-Cell Differentiation
Zinaida Good,
Stanford University, USA
Short Talk: Reverse Fate Mapping of CD19-CAR T Cells in Patients with Lymphoma
Short Talk: Reverse Fate Mapping of CD19-CAR T Cells in Patients with Lymphoma
Elizabeth Maria Zawidzka,
Johns Hopkins University School of Medicine, USA
Short Talk: CD8+ T Cells in the Bone Marrow are Tumor-Specific and Distinct from TILs: Implications for Adoptive Cell Therapy in Solid Tumors
Short Talk: CD8+ T Cells in the Bone Marrow are Tumor-Specific and Distinct from TILs: Implications for Adoptive Cell Therapy in Solid Tumors
Mitra Shourian,
University of Montreal, Canada
Short Talk: Inhibition of IL2Rß Signaling through STAT5 Induces CD8+ T-cell Stemness
Short Talk: Inhibition of IL2Rß Signaling through STAT5 Induces CD8+ T-cell Stemness
17:00—19:00
CRISPR-Cas Biology
Joseph Bondy-Denomy,
University of California, San Francisco, USA
Anti-CRISPRs
Anti-CRISPRs
Kira S. Makarova,
National Center for Biotechnology Information, USA
Evolution and Function of Type III CRISPR-Cas systems
Evolution and Function of Type III CRISPR-Cas systems
Daniela Aliaga Goltsman,
Metagenomi, USA
Short Talk: Novel Families of Compact, Programmable Enzymes for Genome Editing
Short Talk: Novel Families of Compact, Programmable Enzymes for Genome Editing
Michael Schmitz,
University of Zurich, Switzerland
Short Talk: Structural Insights into Target DNA Recognition in Type V CRISPR-Associated Transposon Systems
Short Talk: Structural Insights into Target DNA Recognition in Type V CRISPR-Associated Transposon Systems
17:00—19:00
Epigenetics/Metabolism Re-Wiring
Speaker to be Announced
Ben A. Youngblood,
St. Jude Children's Research Hospital, USA
T Cell Epigenetic Reprograming
T Cell Epigenetic Reprograming
George Coukos,
University Hospital of Lausanne - CHUV, Switzerland
Short Talk: Orthogonal Gene Engineering Enables CD8+ T Cells to Control Tumors through a Novel TOX-indifferent Synthetic Effector State
Short Talk: Orthogonal Gene Engineering Enables CD8+ T Cells to Control Tumors through a Novel TOX-indifferent Synthetic Effector State
Katherine Freitas,
Stanford University, USA
Short Talk: Enhanced Effector Activity of Mediator CDK8 Kinase Module Deficient CAR-T Cells
Short Talk: Enhanced Effector Activity of Mediator CDK8 Kinase Module Deficient CAR-T Cells
Lei Wang,
Massachusetts Institute of Technology, USA
Short Talk: Automated Multi-Step Differentiation From hiPSCs Towards Hematopoietic Lineage Using Endoribonuclease Mediated microRNA-Based Cell-State Sensors
Short Talk: Automated Multi-Step Differentiation From hiPSCs Towards Hematopoietic Lineage Using Endoribonuclease Mediated microRNA-Based Cell-State Sensors
Gillian Carleton,
BC Cancer Victoria, Canada
Short Talk: Metabolic Gene-editing for Enhanced CAR-T Cell Efficacy
Short Talk: Metabolic Gene-editing for Enhanced CAR-T Cell Efficacy
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—11:00
Apps in Basic Biology and Therapy
Coffee Break
Jochen C. Rink,
Max Planck Institute of Biophysical Chemistry, Germany
Against the Odds: Towards Genome Editing in Planarian Flatworms
Against the Odds: Towards Genome Editing in Planarian Flatworms
Fernando D. Camargo,
Boston Children's Hospital, USA
Lineage Tracing with RNA/DNA
Lineage Tracing with RNA/DNA
Saba Parvez,
University of Utah, USA
Short Talk: MIC-Drop: A Platform for Large-Scale CRISPR Screens in vivo
Short Talk: MIC-Drop: A Platform for Large-Scale CRISPR Screens in vivo
Kathy K. Niakan,
Francis Crick Institute, UK
Short Talk: Genetic Approaches to Study Early Lineage Specification in Human Embryos
Short Talk: Genetic Approaches to Study Early Lineage Specification in Human Embryos
08:00—11:00
Cell Manufacturing and Other than Conventional T
Isabelle Riviere,
Memorial Sloan-Kettering Cancer Center, USA
Edited CAR T Cells
Edited CAR T Cells
Peter W. Zandstra,
University of British Columbia, Canada
Short Talk: Signaling Requirements for T-cell Development from Pluripotent Stem Cells
Short Talk: Signaling Requirements for T-cell Development from Pluripotent Stem Cells
Jurgen Kuball,
University Medical Center, Netherlands
Gamma-delta T-Cells
Gamma-delta T-Cells
Coffee Break
Katy Rezvani,
University of Texas MD Anderson Cancer Center, USA
NK Cells
NK Cells
Emma C. Morris,
University College London, UK
Regulatory T Cells
Regulatory T Cells
Sarah Q. Crome,
University Health Network & University of Toronto, Canada
Short Talk: Regulation of Allogeneic T Cells by Human Group 2 and Group 3 Innate Lymphoid Cells
Short Talk: Regulation of Allogeneic T Cells by Human Group 2 and Group 3 Innate Lymphoid Cells
15:00—16:30
Workshop 3: Delivery
Alexandra Birkenshaw,
University of British Columbia, Canada
Improving Transfection Efficiency and Cytotoxicity in HEK293 Cells by using Nanoparticle Delivery Systems
Improving Transfection Efficiency and Cytotoxicity in HEK293 Cells by using Nanoparticle Delivery Systems
Jonathan B. Gilbert,
SQZ Biotechnology, USA
Clinical Translation of Novel Cell Therapies for Diverse Applications using Microfluidic Cell Squeezing
Clinical Translation of Novel Cell Therapies for Diverse Applications using Microfluidic Cell Squeezing
Wayne Ngo,
University of Toronto, Canada
Identifying the Cell Receptors that Recognize the Nanoparticle Protein Corona using Pooled Genome-Wide CRISPR Screens
Identifying the Cell Receptors that Recognize the Nanoparticle Protein Corona using Pooled Genome-Wide CRISPR Screens
Aditya Raguram,
Broad Institute of MIT and Harvard, USA
Therapeutic in vivo Base Editing with Minimal Off-Target Activity via RNP Delivery
Therapeutic in vivo Base Editing with Minimal Off-Target Activity via RNP Delivery
Reka Geczy,
Precision NanoSystems Inc., Canada
A Novel RNA Lipid Nanoparticle Platform: Gene-Edited CAR T Cells for Off-the-Shelf Cancer Therapy
A Novel RNA Lipid Nanoparticle Platform: Gene-Edited CAR T Cells for Off-the-Shelf Cancer Therapy
Bin Liu,
University of Massachusetts Medical School, USA
Modular Prime Editing Platforms
Modular Prime Editing Platforms
15:00—16:30
Workshop 2: CAR/TCR Target Discovery
Elizabeth Wickman,
St. Jude Graduate School, USA
Chimeric Antigen Receptor T Cells Redirected to the C Domain of Tenascin C for the Immunotherapy of Pediatric Brain and Solid Tumors
Chimeric Antigen Receptor T Cells Redirected to the C Domain of Tenascin C for the Immunotherapy of Pediatric Brain and Solid Tumors
William Sam Nutt†,
University of Washington and Fred Hutchinson Cancer Center, USA
c-Jun Overexpression Maintains High Surface CAR Levels and Enhances CAR-T Cell Activity in an Autochthonous Model of Non-Small Cell Lung Cancer
c-Jun Overexpression Maintains High Surface CAR Levels and Enhances CAR-T Cell Activity in an Autochthonous Model of Non-Small Cell Lung Cancer
Joseph M. Valdez,
Berkeley Lights, USA
A Rapid High-Throughput Workflow for TCR Discovery on Solid Tumors with PolyFunctional Verification
A Rapid High-Throughput Workflow for TCR Discovery on Solid Tumors with PolyFunctional Verification
Tianzi Zhang†,
Fred Hutchinson Cancer Center, USA
A Versatile T Cell Target Reporter System to Rapidly Identify TCRs and their Matching HLA/peptides
A Versatile T Cell Target Reporter System to Rapidly Identify TCRs and their Matching HLA/peptides
Reno Debets,
Erasmus MC Cancer Institute, Netherlands
T Cells Engineered with Natural T cell Receptors Directed against Endogenously Presented Epitopes of a Novel Tumor-selective Target to Treat Triple Negative Breast Cancer
T Cells Engineered with Natural T cell Receptors Directed against Endogenously Presented Epitopes of a Novel Tumor-selective Target to Treat Triple Negative Breast Cancer
Muhammad Ali,
Oslo University Hospital, University of Oslo & Stavanger University Hospital, Norway
Cellular Immunotherapy for B-ALL and T-ALL while Sparing Normal Lymphocytes
Cellular Immunotherapy for B-ALL and T-ALL while Sparing Normal Lymphocytes
17:00—19:15
Apps in Plants and Animals
Caixia Gao,
Chinese Academy of Sciences, China
Remote Presentation: Engineering Plants
Remote Presentation: Engineering Plants
Jon Oatley,
Washington State University, USA
Editing Animals
Editing Animals
Jin-Soo Kim,
Institute for Basic Science, South Korea
Remote Presentation: Organelle DNA Editing in Animals and Plants
Remote Presentation: Organelle DNA Editing in Animals and Plants
Hyo Jin Kim†,
Seoul National University, South Korea
Short Talk: Improved Monascus azaphilone Pigment Production in the Filamentous Fungus Monascus ruber by CRISPR-Based Engineering
Short Talk: Improved Monascus azaphilone Pigment Production in the Filamentous Fungus Monascus ruber by CRISPR-Based Engineering
17:00—18:45
Target Discovery
Sebastian Amigorena,
Institut Curie, France
E-Antigens
E-Antigens
Stephen J. Elledge,
Harvard Medical School, USA
T-Scan
T-Scan
Catherine J. Wu,
Dana-Farber Cancer Institute, USA
Neo-antigens
Neo-antigens
Thomas Kuilman,
Neogene Therapeutics, Netherlands
Short Talk: Development of a Personalized Neo-antigen Specific TCR Discovery Platform
Short Talk: Development of a Personalized Neo-antigen Specific TCR Discovery Platform
18:45—19:00
Meeting Wrap-Up: Outcomes and Future Directions
Michel Sadelain,
Memorial Sloan Kettering Cancer Center, USA
19:30—20:30
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
*Session Chair †Invited, not yet responded.
Keystone Symposia thanks our Sponsors(s) for generously supporting this meeting:
|
|
|
|
|
|
We gratefully acknowledge additional support from these exhibitors at this conference:
|
|
|
|
Please stop by to meet these exhibitors during the conference.
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
|
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: John Monson,
Director of Corporate Relations, Email: johnm@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Nick Dua, Senior Director, Communications, Email: nickd@keystonesymposia.org, Phone:+1 970-262-1179 |
